Industry And Regulators Thrash Out Brexit Concerns At Stakeholder Meeting
Executive Summary
Regulators and industry shared their concerns about preparedness, legal uncertainties and the regulatory and supply chain implications of Brexit at a recent stakeholder meeting at the European Medicines Agency.
You may also be interested in...
EMA Redistributes Responsibility For 370 Drugs Currently Overseen By UK
The EMA has completed the reallocation to the EU27 member states of more than 370 centrally authorized drugs for which the UK was rapporteur or co-rapporteur. The move has been necessitated by Brexit, which means the UK will no longer play an active role in new drug evaluations at the EMA.
‘Do Not Rely On The Brexit Transition Period!’ EC Warns Hesitant Pharma Firms
Pharmaceutical companies have been urged by the European Commission to press ahead with their contingency planning for Brexit, amid signs some firms are taking a “wait-and-see” approach.
Coronavirus Notebook: An Accidental Oxford Half Dose, And EU Finally Seals Moderna Vaccine Deal
EU and UK regulators are vying for vaccine filings, and the EMA will consider changing the terms of the marketing authorization for remdesivir after a WHO panel advised against its use in COVID-19. An Austrian biotech firm is investigating the prophylactic potential of a carrageenan-based spray.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: